FAGRB Stock Overview

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. More details

FAGRB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	3/6
Financial Health	4/6
Dividends	2/6

Rewards

Trading at 14% below our estimate of its fair value

Earnings are forecast to grow 11.89% per year

Earnings have grown 7.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Fagron NV Competitors

CVS Group

AIM:CVSG

UK£932.6m

Spire Healthcare Group

LSE:SPI

UK£818.8m

Craneware

AIM:CRW

UK£626.8m

Advanced Medical Solutions Group

AIM:AMS

UK£413.7m

Price History & Performance

Summary of share price highs, lows and changes for Fagron
Historical stock prices
Current Share Price	€19.14
52 Week High	€19.14
52 Week Low	€18.72
Beta	0.21
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	49.65%

Recent updates

Shareholder Returns

	FAGRB	GB Healthcare	GB Market
7D	0%	1.2%	-0.3%
1Y	n/a	-2.4%	-0.7%

Return vs Industry: Insufficient data to determine how FAGRB performed against the UK Healthcare industry.

Return vs Market: Insufficient data to determine how FAGRB performed against the UK Market.

Price Volatility

Is FAGRB's price volatile compared to industry and market?
FAGRB volatility
FAGRB Average Weekly Movement	n/a
Healthcare Industry Average Movement	6.9%
Market Average Movement	5.7%
10% most volatile stocks in GB Market	10.9%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: FAGRB's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine FAGRB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	3,828	Rafael Padilla	www.fagron.com

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments.

Fagron NV Fundamentals Summary

How do Fagron's earnings and revenue compare to its market cap?
FAGRB fundamental statistics
Market cap	€1.56b
Earnings (TTM)	€80.55m
Revenue (TTM)	€871.96m

19.3x

P/E Ratio

1.8x

P/S Ratio

Is FAGRB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FAGRB income statement (TTM)
Revenue	€871.96m
Cost of Revenue	€476.28m
Gross Profit	€395.68m
Other Expenses	€315.12m
Earnings	€80.55m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 31, 2025

Earnings per share (EPS)	1.11
Gross Margin	45.38%
Net Profit Margin	9.24%
Debt/Equity Ratio	67.8%

How did FAGRB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

32%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/10 15:02
End of Day Share Price	2025/03/24 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fagron NV is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Jan Vos	ABN AMRO Bank N.V.
Marc Leemans	Banque Degroof
Beatrice Fairbairn	Berenberg